Boai NKY medical Holdings Ltd. (hereinafter referred to as NKY), stock code: 300109. The company mainly engaged in the production of PVP series products, PVM / MA copolymer and oral care products; Medical technology services such as early tumor screening, molecular diagnosis and individualized precision medicine based on gene sequencing. At present, xinkaiyuan's subsidiaries include Boai xinkaiyuan (Beijing) Medical Technology Development Co., Ltd., Tianjin Boai xinkaiyuan International Trade Co., Ltd., Tianjin arizi Pharmaceutical Technology Co., Ltd., Boai xinkaiyuan pharmaceutical and Chemical Equipment Co., Ltd., Wuhan Haer Medical Technology Development Co., Ltd., Changsha Sanji Biotechnology Co., Ltd Jingneng Biotechnology (Shanghai) Co., Ltd., overseas subsidiary: Germany Boai NKY Chemical Co., Ltd., overseas joint venture: Japan contract new open source Pharmaceutical Co., Ltd.

Xinkaiyuan is a high-tech enterprise which researches, develops and produces PVP series products in China. In the past 30 years, great progress has been made in improving production technology and automatic control level, improving industrial chain structure, expanding production scale and improving quality management level, which plays an important role in the global PVP industry pattern.